Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01960413 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT01960413 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 46 participants.
The verdict
NCT01960413, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
In this feasibility trial, the investigators will compare participants treated with montelukast and hydroxyurea to those treated with placebo and hydroxyurea for a total of 8 weeks.
Interventions
- DRUG Montelukast added to Hydroxyurea
- DRUG Placebo added to Hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-11 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01960413
The ClinicalTrials.gov registry entry for NCT01960413 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Montelukast added to Hydroxyurea is the first listed.
NCT01960413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01960413 about?
NCT01960413 is a clinical study titled "Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia". In this feasibility trial, the investigators will compare participants treated with montelukast and hydroxyurea to those treated with placebo and hydroxyurea for a total of 8 weeks.
What is the current status of trial NCT01960413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2013-11. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01960413?
The interventions under investigation include: Montelukast added to Hydroxyurea (DRUG), Placebo added to Hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT01960413?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.